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Background: More than 2 million patients(pts) are prescribed warfarin for anticoagulation in the US annually and the annual cost associated with 
warfarin complications is estimated to be $1.1 billion. Pharmacogenomic studies have suggested that CYP2C9 and VKORC1 genetic variants may 
help predict therapeutic warfarin dosing. This pilot, prospective, randomized, single blinded clinical trial was designed to determine if there was a 
clinical benefit to genotype guided therapeutic dosing of warfarin therapy(GTDW) over standard therapeutic dosing of warfarin therapy (STDW) in 
geriatric pts.
Hypothesis: GTDW will reduce bleeding complication rates due to out of range INRs when compared to STDW over a 90 day period in geriatric pts.
Methods: Hospitalized pts >65 years of age requiring warfarin anticoagulation were genotyped. Pts with CYP2C9 and VKROC1 alleles were 
randomized to either a GTDW or STDW algorithm. Once therapeutic INR was reached, all pts were followed in the outpatient anticoagulation clinic 
for 3 months. Demographic data, days to therapeutic INR, and bleeding complication rate were compared in the 2 groups. Continuous variables were 
analyzed using Student’s t test. Fisher’s exact test was used to analyze categorical data.
Results: 56 pts were randomized equally to GTDW and STDW arms. CYP2C9 variance (28% in each arm) and VKORC1 variance (52% in GTDW; 
57% in STDW) were comparable in the 2 groups. Age, gender ratio, ethnicity ratio, race, BMI, concomitant use of statins and amiodarone were 
comparable in the 2 groups. The days to therapeutic INR was lower in the GTDW arm compared to the STDW arm (median 4 vs. 5 days; p<.001). The 
bleeding complication rate over a 90 day follow-up period was lower in the GTWD arm (39%) compared to the STDW arm (14% vs. 39%, p=0.03) 
Hospitalization for a bleeding complication was also lower in the GTDW arm (3% vs. 10%; p=0.03).
Conclusion: This pilot trial clearly demonstrates the clinical benefits of genotype guided therapeutic dosing of warfarin in geriatric patients. Our 
results, if validated in a larger trial will help cement the role of genotype guided therapeutic dosing of warfarin in clinical practice and reduce the 
economic burden of warfarin related complications.
